Cetuximab

Across CCLE and GDSC cell-line panels, response to Cetuximab is significantly associated with the mutation status of multiple genes, with BLOOD_Lymphoma cell lines showing a particularly strong set of associations.

The most reproducible Cetuximab response-associated genes across cancer lineages are DOCK2, SYNE1, and NOTCH1, each associated with drug response in up to 3 lineages. Since the analysis identifies associations rather than directional relationships, both response-to-biomarker and biomarker-to-response views are provided.

Each biomarker is linked to its corresponding Q-omics profile. The box plot shows the strongest observed association, Cetuximab response grouped by DOCK2 status in BLOOD_Lymphoma.

Mutation status biomarkers of Cetuximab response

Ranked by combined sampling and lineage consensus. X-score (response→biomarker) and Y-score (biomarker→response) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BLOOD_Lymphoma	DOCK2 →	+1.784	+0.199	.048	.007	3	3
OESOPHAGUS	SYNE1 →	+2.754	+0.384	.015	.023	3	3
BLOOD_Leukemia	NOTCH1 →	+1.490	+0.095	.010	.038	3	3
LUNG_NSCLC_LUSC	RYR2 →	-1.415	-0.673	.025	.007	3	2
SKIN	SCN10A →	+2.000	+0.249	.041	.005	3	2
BREAST	KMT2C →	+2.710	+0.333	.027	.003	3	2

Each biomarker links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Cetuximab response by DOCK2 status — BLOOD_Lymphoma

Explore this box plot interactively →